By: Benzinga
January 04, 2013 at 10:15 AM EST
UPDATE: Piper Jaffray Initiates Coverage on Cytokinetics with Overweight Rating, $4 PT
In a report published Friday, Piper Jaffray & Co. initiated coverage on Cytokinetics (NASDAQ: CYTK ) with an Overweight rating and $4.00 price target. Piper Jaffray noted, “We are initiating on Cytokinetics with an Overweight rating and $4 price target. In our view, the company's platform for treating diseases by
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here